Abstract
Despite constant advances in cancer treatment, some tumor types continue to have very low morbidity and mortality. The Cancer Genome Atlas (TCGA) consortium has contributed to the identification of genomic and genetic alterations in several tumors. The extensive scientific production resulting from this program has, in general, found tumor subtypes that may be more (or less) resistant to …